The market for bacterial conjunctivitis drugs in the U.S. is highly fragmented with the three leading players, namely, Alcon (a Novartis Company), Akorn, Inc., and Allergan plc, accounting for only 56.5% of the market in 2013. Perrigo Company plc, Valeant Pharmaceuticals International, Inc., Bayer AG, Roche, Pfizer, and Santen are some of the other prominent players in the U.S. bacterial conjunctivitis drugs market. Alcon dominates the market due to several factors such as prudent product pricing, competent marketing strategies, and patented products.
Transparency Market Research reports that the bacterial conjunctivitis drugs market in the U.S. was valued at US$473.3 mn in 2013 and is projected to reach US$439.8 mn in 2024. The report forecasts the market to expand at CAGR of 2.79% from 2012 to 2018 and contract at CAGR (-3.73%) from 2018 to 2024.
Patent Expirations to Cause Negative Impact on Market
Among the various drug classes for treatment of bacterial conjunctivitis, fluoroquinolones dominated the bacterial conjunctivitis drugs market in the U.S. in 2013, accounting for 76.5% of all revenues. This was due to its high efficacy against antibiotic-resistant bacterial strains and broad spectrum activity which led to higher prescriptions compared to other antibiotic drug classes. However, sales of this segment is anticipated to witness a decline in the near future. This negative impact on the market is because of reasons such as patent expirations of leading branded formulations such as Vigamox and Moxeza along with increasing influx of generic formulations.
Increase in Ophthalmic Bacterial Infections to Sustain Demand
Rise in ophthalmic bacterial infections is increasing the demand for anti-bacterial drugs in the U.S. According to a clinical study published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of conjunctivitis cases in the U.S. An article published in Merion Matters in November 2012 in the U.S. also stated that over 4 million cases of bacterial conjunctivitis occur in children and adults each year. These statistics indicate increased incidences of bacterial conjunctivitis in the U.S. which is leading to a proportional increase in demand for bacterial conjunctivitis drugs as well. Moreover, people in various age groups, ranging from neonates to geriatrics, are susceptible to bacterial conjunctivitis which as a result will sustain the demand for these drugs in near future.
Patent Expirations of Fluoroquinolones to Erode Revenues
The increasing genericization of anti-bacterial drugs has led to the manufacture of cheaper drugs with nearly the same effectiveness in treating bacterial infections. This as a result has increased the sales volume, although revenues have reduced considerably. Moreover, the bacterial conjunctivitis drugs market in the U.S. is set for an overhaul with major blockbuster Fluoroquinolones such as Vigamox and Moxeza going off patent in September 2019 while Zymaxid would go off patent in December 2016. Approved ANDAs of most of these molecules would lead to intense generic competition. Additionally, burgeoning multi-drug resistant bacterial strains are also expected to hinder market growth. According to the author of this research study, “Implementation of product development partnerships business models and focus on designing and producing combination drug products are opening up new opportunities for the market players.”
The information presented in this review is based on a Transparency Market Research report, titled, “Bacterial Conjunctivitis Drugs Market - U.S. Industry Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2012 - 2024.”
Key Segments of the U.S. Bacterial Conjunctivitis Dugs Market
U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment
- Vancomycin Ophthalmic Ointment
- Early Stage (Phase I and Phase II trials) – Tabular Representation
US Office Contact
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453